Article Text

PDF
Anticoagulation with ▼dabigatran or▼rivaroxaban
  • Relevant BNF section: 2.8.2

Abstract

Anticoagulants such as low molecular weight heparins (LMWH; e.g. enoxaparin) and ▼fondaparinux are cost-effective measures for reducing the likelihood of venous thromboembolism (VTE) in patients undergoing surgery.1 ▼Dabigatran etexilate (Pradaxa-Boehringer Ingelheim)2 and ▼rivaroxaban (Xarelto – Bayer) are fixed-dose oral anticoagulants licensed in the European Union (EU) for the prevention of VTE in adults who have undergone or are undergoing elective replacement of the hip or knee joints.2,3 Here, we consider their place for these indications.

Statistics from Altmetric.com

  • Relevant BNF section: 2.8.2

View Full Text

Footnotes

  • * For an explanation of non-inferiority trials, see DTB 2008; 46: 55–6.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.